BR112015031329A2 - composições compreendendo ciclodextrina e ácido hialurônico reticulado - Google Patents

composições compreendendo ciclodextrina e ácido hialurônico reticulado

Info

Publication number
BR112015031329A2
BR112015031329A2 BR112015031329A BR112015031329A BR112015031329A2 BR 112015031329 A2 BR112015031329 A2 BR 112015031329A2 BR 112015031329 A BR112015031329 A BR 112015031329A BR 112015031329 A BR112015031329 A BR 112015031329A BR 112015031329 A2 BR112015031329 A2 BR 112015031329A2
Authority
BR
Brazil
Prior art keywords
hyaluronic acid
cross
compositions
cyclodextrin
linking agent
Prior art date
Application number
BR112015031329A
Other languages
English (en)
Inventor
Guy Boiteau Jean
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112015031329A2 publication Critical patent/BR112015031329A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composições compreendendo ciclodextrina e ácido hialurônico reticulado” a presente invenção refere-se a uma composição de ácido hialurônico que compreende um ácido hialurônico e uma ou mais moléculas de ciclodextrina covalentemente ligadas ao referido ácido hialurônico através de um agente de reticulação bi- ou polifuncional, em que as ligações covalentes entre o referido ácido hialurônico e o referido agente de reticulação e entre o referido agente de reticulação e as referidas moléculas de ciclodextrina são ligações éter. a presente invenção refere-se a utilizações medicinais e cosméticas (não-medicinais) de tais composições que compreendem ainda um agente farmacêutico ou médico e a um método de preparação de uma formulação de liberação lenta.
BR112015031329A 2013-06-14 2014-06-09 composições compreendendo ciclodextrina e ácido hialurônico reticulado BR112015031329A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361834952P 2013-06-14 2013-06-14
PCT/EP2014/061942 WO2014198683A2 (en) 2013-06-14 2014-06-09 Ha with cyclodextrins

Publications (1)

Publication Number Publication Date
BR112015031329A2 true BR112015031329A2 (pt) 2017-07-25

Family

ID=50896312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031329A BR112015031329A2 (pt) 2013-06-14 2014-06-09 composições compreendendo ciclodextrina e ácido hialurônico reticulado

Country Status (12)

Country Link
US (1) US20160129134A1 (pt)
EP (1) EP3007708A2 (pt)
JP (1) JP2016524644A (pt)
KR (1) KR20160020509A (pt)
CN (1) CN105451744A (pt)
AU (1) AU2014280303A1 (pt)
BR (1) BR112015031329A2 (pt)
CA (1) CA2914765A1 (pt)
HK (1) HK1223033A1 (pt)
MX (1) MX2015017273A (pt)
RU (1) RU2016100874A (pt)
WO (1) WO2014198683A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2791180T3 (es) * 2012-10-02 2020-11-03 Allergan Inc Hidrogeles de relleno dérmico con complejos de inclusión de vitamina A/ciclodextrina
CA2950050A1 (en) * 2014-05-29 2015-12-03 Galderma S.A. Cross-linked hyaluronic acid grafted with dextran
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
WO2019002369A1 (en) * 2017-06-28 2019-01-03 Nestlé Skin Health Sa GLYCOSAMINOGLYCAN HYDROGEL WITH DEXTRANE OR GRAFT CYCLODEXTRIN
IT201800007683A1 (it) * 2018-07-31 2020-01-31 Altergon Sa Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
CN111494648B (zh) * 2020-05-14 2021-10-22 清华大学 润滑载药纳米球、药物及其制备方法
CN111850086B (zh) * 2020-07-29 2023-12-29 丽珠医药集团股份有限公司 注射用伏立康唑的无菌检测方法
JP2024521484A (ja) * 2021-06-17 2024-05-31 メディトックス インク． ヒアルロン酸架橋体、及びそれを含む充填剤組成物
CN114099710A (zh) * 2021-12-13 2022-03-01 中国药科大学 一种促进活性物质皮肤滞留的透明质酸-环糊精纳米载体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282717B6 (sk) * 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
ITTS20000005A1 (it) * 2000-07-24 2002-01-24 Cooperativa Ct Ricerch Epoly T Polisaccaridi coniugati con oligosaccaridi ciclici
EP1951762B1 (en) * 2005-10-03 2018-02-07 PINSKY, Mark A. Compositions and methods for improved skin care
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
CN102698286B (zh) * 2012-07-02 2013-10-09 南开大学 一种靶向传递金刚烷顺铂抗癌前药的超分子组装体及制备
ES2791180T3 (es) * 2012-10-02 2020-11-03 Allergan Inc Hidrogeles de relleno dérmico con complejos de inclusión de vitamina A/ciclodextrina

Also Published As

Publication number Publication date
AU2014280303A1 (en) 2016-02-04
WO2014198683A2 (en) 2014-12-18
RU2016100874A (ru) 2017-07-20
JP2016524644A (ja) 2016-08-18
RU2016100874A3 (pt) 2018-05-25
EP3007708A2 (en) 2016-04-20
US20160129134A1 (en) 2016-05-12
CN105451744A (zh) 2016-03-30
WO2014198683A3 (en) 2015-02-19
KR20160020509A (ko) 2016-02-23
CA2914765A1 (en) 2014-12-18
MX2015017273A (es) 2016-08-03
HK1223033A1 (zh) 2017-07-21

Similar Documents

Publication Publication Date Title
BR112015031329A2 (pt) composições compreendendo ciclodextrina e ácido hialurônico reticulado
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112018010683A8 (pt) ?composição, método para produzir uma composição, método que compreende administrar por via enteral uma substância e método para produzir um produto?
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR132022001907E2 (pt) Partículas de nanoalume contendo um agente de dimensionamento
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112019000692A8 (pt) Moduladores de somatostatina e usos destes
BR112014026117A2 (pt) composições para higiene pessoal
BR112019024747A2 (pt) formulações de dose fixa
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
GB201020193D0 (en) Glucan compositions
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
BR112015009105A2 (pt) esfera, polímero de hialuronato e glucomanana, usos de um polímero de hialuronato e glucomanana e de uma esfera, composição cosmética ou dermatológica para administração tópica, e, processo para sintetizar uma esfera
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112015015411A2 (pt) uso cosmético, processo para a preparação de mips, polímero de impressão molecular, composição cosmética e processo cosmético
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112015010392A8 (pt) Composição para tratamento de pele
MX2015013148A (es) Nuevos compuestos de bencensulfonamida, metodo para sintetizar los mismos, y uso de los mismos en medicina asi como tambien en cosmeticos.
MX2016007534A (es) Composicion de gel de acido hialuronico que tiene durabilidad.
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]